Insider Activity · SEC Form 4
Artiva Biotherapeutics, Inc. (ARTV) Insider Trading
Artiva Biotherapeutics is a clinical-stage biotech developing off-the-shelf NK-cell-based therapies for autoimmune and oncology indications. Small-cap with binary trial outcome risk; lupus and renal-disease readouts are the watched catalysts.
Buys: 4 · $8.67M
Sales: 6 · $477.8K
Recent insider transactions
| Insider | Type | Shares | Price | Value | Date | Source |
|---|---|---|---|---|---|---|
| Shah Rajeev M.Director | BUY | 264,586 | $9.76 | $2.58M | Jul 23, 2026 | Form 4 → |
| Shah Rajeev M.Director | BUY | 160,354 | $8.93 | $1.43M | Jul 17, 2026 | Form 4 → |
| Shah Rajeev M.Director | BUY | 6,522 | $8.94 | $58.3K | Jul 13, 2026 | Form 4 → |
| Shah Rajeev M.Director | BUY | 531,326 | $8.66 | $4.60M | Jun 16, 2026 | Form 4 → |
| Raymon HeatherSVP, Research and Development | SELL | 3,095 | $9.01 | $27.9K | May 19, 2026 | Form 4 → |
| Horan ChristopherChief Tech Operations Officer | SELL | 7,002 | $9.01 | $63.1K | May 19, 2026 | Form 4 → |
| Bush JenniferCOO, CLO, Compliance Officer | SELL | 8,790 | $9.01 | $79.2K | May 19, 2026 | Form 4 → |
| Banerjee SubhashisChief Medical Officer | SELL | 7,037 | $9.01 | $63.4K | May 19, 2026 | Form 4 → |
| Aslan FredChief Executive Officer | SELL | 27,116 | $9.01 | $244.3K | May 19, 2026 | Form 4 → |
| Miralles Gines DiegoPresident & Head of R&D | SELL | 77,500 | — | — | May 18, 2026 | Form 4 → |